Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Future PC-SPES research

This article was originally published in The Tan Sheet

Executive Summary

UCLA's Center for Human Nutrition is working with PC-SPES inventor Sophie Chen to ensure future research of the recalled herbal blend, according to UCLA Division of Clinical Nutrition Director David Heber, MD/PhD. "The strategies and details for manufacturing enough material for the ongoing...clinical trials in a properly controlled manufacturing environment are being actively developed," Heber noted during a House Government Reform Committee hearing July 25. PC-SPES was recalled in February due to contamination with warfarin, but Heber and colleagues believe the herbal mixture may inhibit cancer cell growth. Separately, the UCLA researcher filed an IND with FDA in mid-June to conduct metabolic studies comparing red yeast rice and Merck's cholesterol-lowering drug Mevacor...

You may also be interested in...



PC-SPES research

Herbal mixture "significantly suppressed cell proliferation in colon cancer cell lines" after 72 hours of exposure, Sergio Huerta, UCLA, et al., report in September Cancer Research. In an in vitro study, 11 female mice were given 250 mg/kg/day PC-SPES (Botanic Lab) five times a week for 10 weeks, while 10 mice in placebo group were given .2 mL "vehicle solution." Researchers also report results of in vivo study demonstrating oral PC-SPES-treated mice saw a "significant decrease in polyp number in the medial and distal segments of the small intestines." Huerta et al. conclude the supplement has "potent anticancer effects and results in both cell cycle arrest and apoptosis." UCLA is working with PC-SPES inventor to guarantee future research on herbal blend, which has been plagued by Rx contamination problems (1"The Tan Sheet" Aug. 5, 2002, In Brief)...

European SEAC Opinion Unchanged: Microplastics Must Be Out Of All Cosmetics Within Six Years

The final opinion of ECHA’s Socio-Economic Analysis Committee, published on 1 March, is largely unchanged from its July 2020 draft opinion with regard to microplastic in cosmetic products. That means industry may have to convince EU member state authorities that the restriction proposal has a serious proportionality problem.

QUOTED. 2 March 2021. Michael Coyle.

Representatives from cardiac monitoring device manufacturers and professional societies are working together to persuade Medicare carrier Novitas to reconsider its payment rates for extended cardiac monitoring. See what Michael Coyle, iRhythm’s CEO, said about it here.

Topics

UsernamePublicRestriction

Register

LL1129949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel